IPSEN
5.8.2022 07:02:10 CEST | Business Wire | Press release
Regulatory News:
Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Share, until 11:59 p.m., Eastern time on Thursday 11 August 2022, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., Eastern time, on Monday 8 August 2022. All other terms and conditions of the tender offer remain unchanged.
Each CVR represents the right to receive one or more payments in cash, of up to $1.00 per CVR, contingent upon the achievement of certain milestones upon the terms and subject to the conditions described in the Offer to Purchase dated 12 July 2022 (together with any amendments or supplements thereto, the ‘Offer to Purchase’) and in the related Letter of Transmittal.
The tender offer was extended to allow additional time for the condition relating to the expiration or termination of the waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 as amended (the HSR Condition), to be satisfied.
Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has indicated that, as of 5:00 p.m., Eastern time, on 4 August 2022, approximately 42,256,760 Shares had been validly tendered into and not validly withdrawn from the tender offer, representing approximately 25% of the Shares outstanding as of 6 July 2022. Stockholders who have already tendered their Shares into the tender offer do not have to re-tender their Shares or take any other action as a result of the extension of the expiration time of the tender offer.
Completion of the tender offer remains subject to additional conditions described in the Tender Offer Statement on Schedule TO (as may be amended or supplemented) filed by Purchaser, Ipsen Biopharmaceuticals, Inc., Ipsen Pharma SAS and Ipsen S.A., with the United States Securities and Exchange Commission (SEC) on 12 July 2022. Such conditions include there having been validly tendered and not validly withdrawn Shares that, considered together with all other Shares (if any) beneficially owned by Ipsen Pharma SAS and its subsidiaries, represent at least one Share more than 50% of the total number of Shares outstanding immediately prior to the expiration of the Offer (including any extensions).
Requests for documents and questions regarding the tender offer may be directed to Georgeson LLC, the Information Agent for the tender offer, by telephone (toll-free) at (866) 203-9357 or by email at epizyme@georgeson.com .
ENDS
About Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com
Additional Information and Where to Find It
This communication does not constitute an offer to buy or solicitation of an offer to sell Shares. This communication is for informational purposes only. The tender offer is not being made to, nor will tenders be accepted from, or on behalf of, holders of Shares in any jurisdictions in which the making of the tender offer or the acceptance thereof would not comply with the laws of that jurisdiction.
The tender offer is being made pursuant to a Tender Offer Statement on Schedule TO (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) filed by Purchaser, Ipsen Biopharmaceuticals, Inc., Ipsen Pharma SAS and Ipsen S.A. with the SEC on July 12, 2022, as amended or supplemented from time to time. In addition, on 12 July 2022, Epizyme filed a Solicitation/Recommendation Statement on Schedule 14D-9 (as amended or supplemented from time to time, the Solicitation/Recommendation Statement) with the SEC related to the tender offer. EPIZYME’S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Shares at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement are available free of charge at the SEC’s website at www.sec.gov .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804006066/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nearly Nine in 10 Private Capital GPs Face Data Validation Challenges10.11.2026 15:00:00 CET | Press release
88% of GPs say finance and operations teams spend 11% to 50% of their time validating, reconciling, recalculating, or recreating administrator outputs70% of GPs are targeting outsourced or strategic co-sourced operating models, while 97% of LPs expect outsourcing to specialist providers to increase74% of LPs identify IT systems and cybersecurity as important to operational due diligence, while 59% want a documented AI and data governance framework shared during due diligence Nearly nine in 10 (88%) of private capital general partners (GPs) surveyed say their finance and operations teams spend between 11% and 50% of their time validating, reconciling, recalculating or recreating administrator outputs, according to new research from CSC, the leading provider of global business administration and compliance solutions¹. CSC surveyed more than 300 GPs and 200 limited partners (LPs) across North America, Europe, the U.K., and Asia Pacific. The report, Future Private Capital CFO 2026, examine
80% of IT Leaders Say the Digital Workplace Is Critical to AI Success, Yet Only 10% Have Fundamentally Redesigned It, Lenovo Research Finds10.11.2026 15:00:00 CET | Press release
Global study of 1,200 IT leaders identifies five connected dimensions of workplace readiness and shows where organizations can focus to turn AI ambition into measurable business value Eight in ten IT decision makers say the digital workplace is critical to successful AI-led transformation, yet only 10% report fundamentally redesigning it for AI, according to Lenovo’s sixth Work Reborn report, The AI-ready workplace. The findings expose a significant gap between deploying AI tools and the operating capabilities needed to integrate them into how work gets done across an organization. The report frames workplace readiness as a connected system spanning people, workflows, technology, support and governance, with each contributing to how enterprises translate AI ambition into business outcomes at scale. Based on an August 2026 survey of 1,200 IT leaders at organizations with at least 1,000 employees across 12 countries, the report examines the workplace conditions needed to translate AI dep
The $63.4 Billion Innovation Drain: Study Finds Unexpected Tech Costs Force Cuts into AI Investment and Hiring10.11.2026 15:00:00 CET | Press release
New economic research reveals how unpredictable infrastructure costs are constraining innovation, with potential savings that could support more than 111,000 jobs and generate $20.4 billion in long-term growthAI/ML infrastructure overspend is the most of any technology category at 37% ($23.4bn) of the total, and nearly twice as hard to forecast84% of organizations made at least one cost-driven trade-off over the past year Businesses across eight major economies incur $63.4 billion annually in technology infrastructure overspend attributable to opaque, unpredictable or difficult-to-forecast provider charges, forcing companies to scale back investments in artificial intelligence, hiring and new product development, according to new economic research from the Centre for Economics and Business Research (CEBR), commissioned by Wasabi Technologies. The overspend reflects infrastructure provider charges businesses could not forecast, rather than their own planned usage. AI and machine learnin
Echodyne EchoShield® Selected for BAE Systems Anti Threat System10.11.2026 15:00:00 CET | Press release
High-fidelity MESA® radar data strengthens BATS’ integrated “sense, decide, effect” mission chain Echodyne, the radar platform company, today announced that its EchoShield radar has been selected and integrated into the BAE Systems Anti Threat System (BATS), providing the precise, persistent airspace data required to detect, classify, track and respond to uncrewed threats. BATS recently completed live trials in Scotland, demonstrating its ability to integrate multiple sensors and effectors through a single command-and-control architecture to identify and respond to evolving drone threats in real time. EchoShield® has been selected as one of the sensors supporting this open and interoperable architecture. BAE Systems is Europe’s largest defense company with its equipment, systems and services fielded by more than 25 European nations. BATS is a modular, software-defined counter-uncrewed systems capability that connects current and future sensors and effectors through a secure, resilient
GigaDevice Launches New-Generation GD32H7 High-Performance MCU Portfolio for Full-Scenario Industrial Applications10.11.2026 15:00:00 CET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, officially launches its new-generation GD32H7 MCU portfolio built on a unified chip architecture. Developed from a homologous silicon die with tailored IP configuration, peripheral optimization and scenario-specific tuning, the comprehensive product lineup precisely covers three core industrial application scenarios: industrial HMI human-machine interaction, general industrial automation, and robotic servo joint control. It delivers industrial manufacturers with a high-performance, fully integrated MCU solution featuring unified architecture, clear product classification and exceptional development reusability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110874769/en/ GigaDevice New-Generation GD32H7 High-Performance MCU Universal Core Hardware Features – Building a Unified High-Perfor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom